πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

404 results for β€œtreatment” Clear

  1. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  2. CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Ipsen

    Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

    phase 2 small molecule active

    1 trial

  3. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  4. CAR-T treatment

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  5. CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  6. CD25 antibody combined glucocorticoid as first-line treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Graft Versus Host Disease

    phase 2 small molecule active

    1 trial

  7. CIALIS 5 mg film-coated tablets

    The George Institute

    sexual/ erectile function in women and men after treatment for rectal cancer

    phase 2 small molecule active

    1 trial

  8. CND261

    Lacuna Pharma Pty Ltd

    Active, treatment refractory, ANCA-IgG-positive associated vasculitis

    phase 2 small molecule active

    1 trial

  9. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  10. Cizutamig

    Lacuna Pharma Pty Ltd

    Severe, treatment refractory primary SjΓΆgren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    phase 2 small molecule active

    1 trial

  11. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Graft Versus Host Disease

    phase 2 other completed

    1 trial

  12. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  13. Description and Composition of the Placebo β€’ Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. β€’ Pharmaceutical form: solution (oil) β€’ Route of administration: oral β€’ Storage: Store tightly closed below 25Β°C and protected from light like the verum form. β€’ Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  14. EDP-420 / Duration of Treatment - 3 days

    ENANTA PHARMACEUTICALS INC

    Community Acquired Pneumonia

    phase 2 small molecule active

    1 trial

  15. ELACESTRANT

    Fondazione Telethon ETS

    Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)

    phase 2 small molecule active

    1 trial

  16. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  17. Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion

    Biogen

    Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

    phase 2 small molecule active

    1 trial

  18. Fibromun, Darleukin

    Philogen S.p.A.

    Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

    phase 2 small molecule active

    1 trial

  19. Gemcitabine

    BRIGHT MINDS BIOSCIENCES INC.

    Treatment Refusal

    phase 2 small molecule active

    1 trial

  20. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  21. HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  22. Humanized IgG1 monoclonal antibody against GD2, Leukine

    Y-Mabs Therapeutics A/S

    Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

    phase 2 small molecule active

    1 trial

  23. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  24. IPN10200 placebo, DYSPORT 300 UNITES SPEYWOOD, poudre pour solution injectable, IPN10200

    Ipsen

    Treatment of Moderate to Severe Upper Facial Lines

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources